Tokai and Viking set IPO terms

Tokai Pharmaceuticals Inc. (Cambridge, Mass.) and Viking Therapeutics Inc. (San Diego, Calif.) both set terms for planned IPOs on NASDAQ.

Tokai plans to sell of 5.4 million shares at $13-$15. At $14, the company would raise $75.6 million and would be valued at $290.7 million. Tokai filed to raise up to $75 million in the offering last month. BMO Capital Markets; Stifel; William Blair; and Janney Montgomery Scott are underwriters. Next half, Tokai plans to start Phase III trials of galeterone ( TOK-001) to treat castration-resistant prostate cancer (CRPC). The compound is an oral small molecule androgen receptor antagonist and degrader that also inhibits cytochrome P450 17 alpha-hydroxylase/C17, 20 lyase (CYP17) inhibitor. ...